- What changed in ANIK news today?
- Anika raises 2026 outlook as Q3 revenue grows 10%: Anika Therapeutics’ third-quarter 2026 revenue rose 10% year over year to $30.59 million, with commercial channel revenue up 17%; adjusted net income was $3.9 million despite a $311,000 net loss. It raised its 2026 revenue growth and adjusted EBITDA margin outlook and expects 2027 revenue growth of flat to 5%.
- Does Rallies summarize ANIK news?
- Yes. Rallies summarizes ANIK news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
- Is ANIK research on Rallies investment advice?
- No. Rallies provides research, data, and educational context for ANIK. It does not provide personalized investment advice.
